SAN CLEMENTE, Calif., Dec. 13, 2011 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ: ICUI) announced that a clinical study presented at the American Society of Nephrology's (ASN) Kidney Week 2011 showed the Tego® needlefree hemodialysis connector can decrease heparin use and reduce costs for dialysis clinics. As the world's first and only needlefree connector FDA-cleared for use in hemodialysis applications, the Tego connector provides a cost effective alternative to traditional connectors without affecting blood flow rate or the rate of positive blood cultures.
For the study titled Tego® Connectors Reduce Heparin Use without Affecting Blood Flow Rate Compared to Traditional Central Venous Catheter Locks, researchers from DaVita Clinical Researchä (DCR), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, analyzed clinical data from more than 2,500 patients, comparing conversion from traditional central venous catheter (CVC) locks to Tego connectors. Researchers examined data gathered 90 days before and 90 days immediately following the Tego conversion, evaluating blood flow rate, heparin use, and blood culture results. From this data, a cost analysis was conducted, comparing the cost of heparin, connectors, syringes, activase, sodium citrate, and equipment for both CVC locks and Tego connectors to the cost of recombinant tissue plasminogen activator (rt-PA).
Researchers showed that total heparin use decreased by nearly 2000 units three months after the Tego conversion, reducing costs by an average of $16.38 per CVC compared to traditional CVC locks, and "significantly" reducing costs when compared to rt-PA. This study provides evidence to support the Tego's ability to reduce costs associated with long-term CVC without the use of heparin CVC
|SOURCE ICU Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved